Compare SXC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | ACHV |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.2M | 726.5M |
| IPO Year | 2011 | 2018 |
| Metric | SXC | ACHV |
|---|---|---|
| Price | $9.86 | $8.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $14.67 |
| AVG Volume (30 Days) | 834.3K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,600,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $95.00 | ★ N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $2.62 |
| 52 Week High | $10.68 | $8.64 |
| Indicator | SXC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 60.88 |
| Support Level | $7.64 | $4.03 |
| Resistance Level | $9.79 | $8.63 |
| Average True Range (ATR) | 0.33 | 0.37 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 19.01 | 75.46 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.